Melanoma trials recruiting in District of Columbia

All Melanoma trials nationally

Cities in District of Columbia

Recruiting trials in District of Columbia

• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
  NCT06581406 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: All (male and female) · District of Columbia: Washington D.C.
• Cancer Experience Registry (CER) for Cancer Patients and Caregivers
  NCT02333604 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
  NCT05896839 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
  NCT03860883 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Project: Every Child for Younger Patients With Cancer
  NCT02402244 · Phase: Not specified · Ages: Up to 25 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
  NCT06585410 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
  NCT06070012 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
  NCT04851119 · Phase: Phase 1, Phase 2 · Ages: 12 Months to 30 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
  NCT06264180 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
  NCT04389281 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.